ALK and neuroblastoma: In neuroblastoma, where ALK is activated by point mutations in the TKD of the full-length receptor, prior ALK inhibition did not appear to impact the time (or development) of on-target resistance, contrasting with the experience in ALK fusion NCLSC13—noting that our assessment is limited by the relatively small number of patients studied here.